Boehringer Ingelheim Selects Veeva Development Cloud Worldwide to Bring Innovative Therapies to Patients Faster

Boehringer Ingelheim and Veeva Systems announced Boehringer Ingelheim’s selection of Veeva Development Cloud to drive end-to-end processes and seamless information sharing for greater speed in the delivery of innovative therapies. Boehringer Ingelheim, a leading research-driven biopharmaceutical company, is working on breakthrough therapies that improve the lives of humans and animals and creating value through innovation in areas of high unmet medical need. By bringing together data and processes across clinical, regulatory, and quality on a single cloud platform for the enterprise, Boehringer Ingelheim will establish a connected technology landscape for agile collaboration that can accelerate the development of novel medicines.

The transformation is part of Boehringer Ingelheim’s Medicine Excellence initiative that harnesses technology with the aim to build a ‘One Medicine Platform,’ unifying development processes and data in a centralized platform. Veeva’s technology will help make this vision a reality. With Veeva Development Cloud, Boehringer Ingelheim will further streamline its IT infrastructure and deliver a more consistent user experience, making it easier to access information and collaborate cross-functionally.

Recommended AI News: One of World’s Largest Venue Management Companies Signs Million-Dollar Deal With Darktrace

“We believe in advancing health through partnerships and are excited to embark on this journey, strengthening our ability to create a positive impact on patient lives,” said Uli Brödl, senior vice president, global clinical development and operations at Boehringer Ingelheim. “Veeva Development Cloud will enable cross-functional teams to work more collaboratively and leverage data and insights, enhancing their ways of working.”

As part of Veeva Development Cloud, Boehringer Ingelheim will accelerate clinical development with Vault CDMS, Vault CTMS, Vault eTMF, Vault Study Start-up, and Vault Payments, streamline regulatory activities with Vault Registrations, Vault Submissions, Vault Submissions Publishing, and Vault Submissions Archive, and simplify quality processes with Vault QMS and Vault QualityDocs. The company will also start its journey with the Veeva Digital Trials Platform, using Veeva Site Connect to automate information flow with partner research sites.

Recommended AI News: Credera Attains AWS Well-Architected Partner Program Membership

“Using Veeva’s next-generation clinical data management and operations applications in tandem with regulatory and quality will allow us to open borders between functions for continuous improvement,” said Thomas Reith, senior vice president, head of IT research, development, and medicine at Boehringer Ingelheim. “With unified data and processes, we can reduce complexity and develop an innovative, digital culture to better understand and solve medical needs.”

“Boehringer Ingelheim and Veeva have had an outstanding partnership for more than 10 years, starting in the commercial area. Our teams share a spirit of innovation, customer-centricity, and long-term thinking,” said Peter Gassner, Veeva founder and CEO. “We’re excited and honored to enter this next stage of our partnership.”

“Boehringer Ingelheim is shaping the future of healthcare by embracing new ways of solving old challenges,” concluded Rik Van Mol, senior vice president, Veeva Development Cloud. “We’re proud to be a trusted partner to advance R&D while empowering the company’s employees with data and an improved, familiar user experience throughout their business processes.”

Recommended AI News: Talkwalker Reveals How Brands Can Leverage Consumer Intelligence to ‘Shape Tomorrow’ for Growth

[To share your insights with us, please write to sghosh@martechseries.com]